Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban
- 1 January 2016
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 116 (07), 191-197
- https://doi.org/10.1160/th16-01-0004
Abstract
Thrombosis and Haemostasis publishes original basic research and clinical studies in vascular biology and medicine, serving as an international platform for dissemination and debate of scientific information at the cutting edge.Funding Information
- German Federal Ministry of Education and Research (BMBF 01E01003)
This publication has 23 references indexed in Scilit:
- European Union-28: An annualised cost-of-illness model for venous thromboembolismThrombosis and Haemostasis, 2016
- Management of venous thrombo-embolism: an updateEuropean Heart Journal, 2014
- Thrombosis: A major contributor to global disease burdenThrombosis and Haemostasis, 2014
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismThe New England Journal of Medicine, 2013
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismThe New England Journal of Medicine, 2012
- Venous thromboembolism: Annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack ratesThrombosis and Haemostasis, 2012
- Outpatient treatment in patients with acute pulmonary embolism: the Hestia StudyJournal of Thrombosis and Haemostasis, 2011
- Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trialThe Lancet, 2011
- Home treatment in pulmonary embolismThrombosis Research, 2010
- Out of hospital treatment of acute pulmonary embolism in patients with a low NT‐proBNP levelJournal of Thrombosis and Haemostasis, 2010